

2016 Prior Authorization (PA) Criteria

Certain drugs require prior authorization from GuildNet Gold Plus FIDA Plan Medicare Plans. This means that your doctor must contact us to get approval before prescribing the drug to you. If your doctor does not get prior approval, the drug may not be covered.

This list also includes drugs that may be covered under Medicare Part B or Part D depending on how the drugs are used or administered. If your drug is on this list, your doctor should call us and to provide information describing the use and administration of the drug so we can advise on whether the drug will be covered.

To see if your drug is on the list, refer to the index located at the end of this document for the medication you are looking for.

ACTHAR

Products Affected

- Acthar H.P.

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Use in patients with multiple sclerosis (MS) as pulse therapy on a monthly basis.
Required Medical Information	MS exacerbation, history of corticosteroid use.
Age Restrictions	N/A
Prescriber Restrictions	Infantile spasms, prescribed by or in consultation with a neurologist or an epileptologist. MS exacerbation, prescribed by or in consultation with a neurologist or physician that specializes in the treatment of MS.
Coverage Duration	Infantile spasms, Plan Year. MS exacerbation, approve 1 month.
Other Criteria	For MS exacerbation, approve if the patient cannot use high-dose IV corticosteroids because IV access is not possible or if the patient has tried high-dose corticosteroids administered IV for an acute MS exacerbation and has experienced a severe or limiting adverse effect.

ACTIMMUNE

Products Affected

- Actimmune

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ADCIRCA

Products Affected

- Adcirca

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Nitrate therapy
Required Medical Information	PAH been confirmed by right heart catheterization.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ADEMPAS

Products Affected

- Adempas

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	PAH and CTEPH- must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	Plan Year
Other Criteria	For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). Right heart catheterization is not required in pts who are currently receiving Adempas or another agent indicated for WHO group 1.

AFINITOR

Products Affected

- Afinitor
- Afinitor Disperz

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Oncologist
Coverage Duration	Plan Year
Other Criteria	N/A

ALECENSA

Products Affected

- Alecensa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Patients already started on Alecensa for a covered use
Exclusion Criteria	Xalkori (Crizotinib) treatment naive patients
Required Medical Information	Confirmed ALK-positive NSCLC as detected by an FDA-approved test and prior therapies tried
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	Anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC): The patient has metastatic ALK-positive NSCLC as detected by an FDA-approved test AND The patient has progressed on or are intolerant to Xalkori (crizotinib)

AMPYRA

Products Affected

- Ampyra

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus patient already started on dalfampridine extended-release for Multiple Sclerosis (MS).
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	MS. If prescribed by, or in consultation with, a neurologist or MS specialist.
Coverage Duration	Plan Year
Other Criteria	N/A

ANTICONVULSANTS

Products Affected

- topiramate oral capsule, sprinkle
- topiramate oral capsule, sprinkle, ER 24hr
- topiramate oral tablet
- zonisamide

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

APOKYN

Products Affected

- APOKYN

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

APTIOM

Products Affected

- Aptiom

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ARCALYST

Products Affected

- Arcalyst

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus patient already started on rilonacept for Muckle Wells Syndrome (MWS) or Familial Cold Autoinflammatory Syndrome (FCAS).
Exclusion Criteria	Rilonacept should not be given in combination with biologic therapy (e.g. tumor necrosis factor (TNF) blocking agents (eg, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), anakinra, or canakinumab).
Required Medical Information	N/A
Age Restrictions	Initial tx CAPS-Greater than or equal to 12 years of age.
Prescriber Restrictions	Initial tx CAPS-prescribed by, or in consultation with, a rheumatologist, geneticist, or dermatologist.
Coverage Duration	Plan Year
Other Criteria	CAPS renewal - approve if they have had a response and are continuing therapy to maintain response/remission.

AVONEX

Products Affected

- Avonex (with albumin)
- Avonex intramuscular pen injector kit
- Avonex intramuscular syringe kit

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

BANZEL

Products Affected

- Banzel oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

BOSULIF

Products Affected

- Bosulif

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Bosulif for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Bosulif is being used. For chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) status of the leukemia must be reported. For CML, prior therapies tried must be reported to confirm resistance or intolerance.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For CML, patient must have Ph-positive CML and must have resistance or intolerance to prior therapy for approval.

BRIVIACT

Products Affected

- Briviact

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

CABOMETYX

Products Affected

- Cabometyx

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, medication history, histology, RET gene rearrangement status
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Advance Renal Cell Carcinoma-Patients must meet both 1 AND 2-1. Patient has RCC with predominant clear-cell histology 2. Patient has tried one tyrosine kinase inhibitor therapy (e.g., Sutent [sunitinib malate capsules], Votrient [pazopanib tablets], Inlyta [axitinib tablets], Nexavar [sorafenib tosylate tablets]).

CARBAGLU

Products Affected

- Carbaglu

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

CHOLBAM

Products Affected

- Cholbam

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	baseline liver function tests
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial approval for 3 months, continuation approval for plan year
Other Criteria	For continuation of therapy to be approved patient must meet 2 of the 3 following lab criteria or meet 1 of the 3 follow lab criteria and have body weight increased by 10% or stable at greater than the 50th percentile. Lab criteria: (1) patient alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 50 U/L or the baseline levels reduced by 80%, (2) patient total bilirubin level must be reduced to less than or equal to 1 mg/dL, (3) patient must not have evidence of cholestasis on liver biopsy.

CHORIONIC GONADOTROPINS (HCG)

Products Affected

- chorionic gonadotropin, human
- Novarel
- Pregnyl

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

CIALIS

Products Affected

- Cialis oral tablet 2.5 mg, 5 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Indication for which tadalafil is being prescribed.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Benign prostatic hyperplasia (BPH), after confirmation that tadalafil is being prescribed to treat the signs and symptoms of BPH and not for the treatment of erectile dysfunction (ED) and after a trial of an alpha-1 blocker (eg, doxazosin [Cardura XL], terazosin, tamsulosin [Flomax], alfuzosin extended-release [UroXatral]) or 5 alpha reductase inhibitor (eg, finasteride, dutasteride [Avodart]).

CINRYZE

Products Affected

- Cinryze

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus for the acute treatment of Hereditary Angioedema (HAE).
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Must be prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders.
Coverage Duration	Plan Year
Other Criteria	N/A

COMETRIQ

Products Affected

- Cometriq

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Cometriq for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of progressive, metastatic medullary thyroid cancer.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

COPAXONE

Products Affected

- Copaxone subcutaneous syringe 20 mg/mL, 40 mg/mL
- Glatopa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of any of the following medications: Interferon-beta therapy (Avonex, Betaseron, Extavia, or Rebif), mitoxantrone, fingolimod, teriflunomide, or dimethyl fumarate.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	Patients with previous use (12 or more months) of Copaxone must demonstrate one of the following clinical responses: decrease in the frequency of relapses, slowing of disease progression, diminished MRI lesions, OR patient is stable on therapy.

COTELLIC

Products Affected

- Cotellic

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Previous therapies tried, presence of BRAF V600E or V600K mutation confirmed by an FDA approved test
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	Melanoma - being prescribed in combination with vemurafenib

CYRAMZA

Products Affected

- Cyramza

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Previous therapies tried
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For gastric cancer or malignant neoplasm of cardio-esophageal junction of stomach, prior therapy with fluoropyrimidine- or platinum-containing therapy. For metastatic colorectal cancer, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) and prior therapy with Avastin (bevacizumab), oxaliplatin, and a fluoropyrimidine. For metastatic NSCLC, in combination with docetaxel and prior therapy with platinum-based chemotherapy. Part B versus D determination per CMS guidance.

DARZALEX

Products Affected

- Darzalex

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Treatment-naïve patients
Required Medical Information	History of previous treatments
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	For the treatment of Multiple myeloma treatment patients must have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or are double-refractory to a PI and an immunomodulatory agent.

DEMSEER

Products Affected

- Demser

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

DICLOFENAC GEL

Products Affected

- diclofenac sodium topical gel 3 %

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

EGRIFTA

Products Affected

- Egrifta subcutaneous recon soln 1 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis.
Age Restrictions	Adults
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician specializing in the treatment of HIV (eg, infectious disease, oncology).
Coverage Duration	Plan Year
Other Criteria	HIV-infected adult patients (18 years of age or older) with lipodystrophy AND Egrifta is being used to reduce excessive abdominal fat

EMPLICITI

Products Affected

- Empliciti

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Treatment-naïve patients
Required Medical Information	History of previous treatments
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	For the treatment of multiple myeloma, patient must have received at least one prior therapy. Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.

ERIVEDGE

Products Affected

- Erivedge

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patient already started on Erivedge for a covered use.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Locally advanced basal cell carcinoma (LABCC), approve if the patients BCC has recurred following surgery or the patient is not a candidate for surgery or radiation therapy.

ERWINAZE

Products Affected

- Erwinaze

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Documentation of hypersensitivity to Escherichia coli derived asparaginase as a component of a multi-agent chemotherapeutic regimen.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ESBRIET

Products Affected

- Esbriet

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Combination use with Nintedanib
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in combination with a pulmonologist
Coverage Duration	Plan Year
Other Criteria	IPF baseline - must have FVC greater than or equal to 50 percent of the predicted value AND IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP.

EXTAVIA

Products Affected

- Extavia subcutaneous kit

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Concurrent use of any of the following medications: Interferon-beta therapy (Avonex, Betaseron, Extavia, or Rebif), mitoxantrone, fingolimod, teriflunomide, or dimethyl fumarate.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Patients with previous use (12 or more months) of Extavia must demonstrate one of the following clinical responses: decrease in the frequency of relapses, slowing of disease progression, MRI lesions have diminished with therapy, OR patient is stable on therapy.

FARYDAK

Products Affected

- Farydak

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

FERRIPROX

Products Affected

- Ferriprox oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

FIRAZYR

Products Affected

- Firazyr

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders.
Coverage Duration	Plan Year
Other Criteria	N/A

FYCOMPA

Products Affected

- Fycompa oral suspension
- Fycompa oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

GATTEX

Products Affected

- Gattex One-Vial

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

GILOTRIF

Products Affected

- Gilotrif

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Documentation of metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

GLEEVEC

Products Affected

- Gleevec oral tablet 100 mg, 400 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) must be positive for the Philadelphia chromosome or BCR-ABL gene. For CML, patient meets one of the following: 1) newly diagnosed, 2) resistance or intolerance to prior therapy, or 3) recurrence after stem cell transplant. For ALL, patient meets one of the following: 1) newly diagnosed and Gleevec is used in combination with chemotherapy, or 2) ALL is relapsed or refractory. For GIST, patient meets one of the following: 1) unresectable, recurrent, or metastatic disease, or 2) use of Gleevec for adjuvant therapy following resection, or 3) use of Gleevec for pre-operative therapy and patient is at risk for significant surgical morbidity.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

GROWTH HORMONE

Products Affected

- Norditropin FlexPro

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For pediatric GHD in neonate with hypoglycemia: patient has a randomly assessed GH level less than 20 ng/mL, other causes of hypoglycemia have been ruled out, and other treatments have been ineffective. For all pediatric patients: patients have short stature or slow growth velocity and have been evaluated for other causes of growth failure. For pediatric GHD, patient has delayed bone age. For pediatric GHD without pituitary disease, patient failed 2 stimulation tests. For pediatric GHD with a pituitary or CNS disorder, patient has clinical evidence of GHD and low IGF-1/IGFBP3. For TS and SHOX patients: diagnosis confirmed by genetic testing. For CRI patients: metabolic, endocrine and nutritional abnormalities have been treated or stabilized and patient has not had a kidney transplant. For SGA: patient has a low birth weight or length for gestational age. For ISS: pediatric GHD has been ruled out with one stimulation test. For adult GHD, patient was assessed for other causes of GHD-like symptoms. For adult GHD without pituitary disease, patient failed 2 stimulation tests. For adult GHD with at least 3 pituitary hormone deficiencies (PHD) or panhypopituitarism: have a low IGF-1. For adult GHD with less than 3 PHD, low IGF-1 and failed one stimulation test. For renewal for pediatric patients, growing more than 2.5 cm per year and for PWS only: improved body composition. For renewal for adult patients: patient has seen clinical improvement.
Age Restrictions	For Turner syndrome and SGA, 2 years of age and older. For Noonan syndrome and SHOX, 3 years of age and older.
Prescriber Restrictions	Endocrinologist, Pediatric Nephrologist, Gastroenterologist, Nutritional Support Specialist, Infectious Disease Specialist
Coverage Duration	Plan Year
Other Criteria	N/A

HARVONI

Products Affected

- Harvoni

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent treatment with interferon, Sovaldi, Olysio, or Viekira
Required Medical Information	Prior to initiating therapy, detectable levels of HCV RNA in the serum. Genotype 1, 4, 5, 6. Cirrhosis documented by FibroScan, liver biopsy, or radiological imaging
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation w/ GI, hepatologist, ID, or a liver transplant MD
Coverage Duration	24WK: Gen 1-exp w cirr, Gen1/4 trans. 12WK: Gen 1-nv, exp w/o cirr, Gen 4/5/ 6, Gen 1/4 trans +RBV
Other Criteria	N/A

HETLIOZ

Products Affected

- HetlioZ

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For the indication of Non-24-Hour Sleep-Wake Disorder (Non-24), approval will only be granted for patients who are totally blind.

HRM

Products Affected

- benzotropine oral
- butalbital-acetaminop-caf-cod
- clemastine oral tablet 2.68 mg
- cyclobenzaprine oral tablet
- cyproheptadine
- dicyclomine oral capsule
- dicyclomine oral solution
- dicyclomine oral tablet
- Digitek
- digoxin injection solution
- digoxin oral solution 50 mcg/mL
- digoxin oral tablet
- ergoloid
- Lanoxin oral
- meprobamate
- metaxalone
- methyldopa-hydrochlorothiazide
- promethazine oral tablet
- reserpine
- trihexyphenidyl

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy

HRM - BENZODIAZEPINES

Products Affected

- alprazolam
- Lorazepam Intensol
- lorazepam oral tablet
- oxazepam
- temazepam

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Procedure-related sedation = 1mo. All other conditions = Plan Year.
Other Criteria	All medically accepted indications other than Restless Leg Syndrome and insomnia, authorize use. Restless Leg Syndrome, approve clonazepam if the patient has tried one other agent for this condition (eg, ropinirole, pramipexole, carbidopa-levodopa [immediate-release or extended-release]). Insomnia, approve lorazepam, oxazepam, or temazepam if the patient has had a trial with two of the following: ramelteon, trazodone, doxepin 3mg or 6 mg, eszopiclone, zolpidem, or zaleplon.

HRM BENZODIAZEPINES/ANTICONVULSANTS

Products Affected

- clonazepam
- clorazepate dipotassium
- Diastat
- Diazepam Intensol
- diazepam oral solution 5 mg/5 mL (1 mg/mL)
- diazepam oral tablet
- diazepam rectal

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy

HRM PD

Products Affected

- amitriptyline
- clomipramine
- doxepin oral
- estradiol oral
- imipramine HCl
- imipramine pamoate
- megestrol oral tablet
- perphenazine-amitriptyline
- phenobarbital
- Surmontil
- trimipramine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy

HYDROXYPROGESTERONE

Products Affected

- hydroxyprogesterone caproate

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

IBRANCE

Products Affected

- Ibrance

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ICLUSIG

Products Affected

- Iclusig

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ILARIS

Products Affected

- Ilaris (PF)

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	When used in combination with concurrent biologic therapy (e.g. TNF antagonists, etanercept, adalimumab, certolizumab pegol, golimumab, infliximab), anakinra, or rilonacept.
Required Medical Information	N/A
Age Restrictions	CAPS-4 years of age and older. SJIA-2 years of age and older.
Prescriber Restrictions	CAPS/MWS/FCAS initial- Prescribed by or in consultation with a rheumatologist, geneticist, or dermatologist. SJIA initial- prescribed by or in consultation with a rheumatologist
Coverage Duration	Plan Year
Other Criteria	For renewal of CAPS/MWS/FCAS - after pt had been started on Ilaris, approve if the pt had a response to therapy as determined by prescribing physician and the pt is continuing therapy to maintain a response/remission. For treatment of SJIA, initial therapy approve if the pt meets one of the following 1. has tried at least 2 other biologics for SJIA (tocilizumab, abatacept, TNF antagonists (e.g. etanercept, adalimumab, infliximab) OR 2. pt has features of poor prognosis (e.g. arthritis of the hip, radiographic damage, 6-month duration of significant active systemic disease, defined by fever, elevated inflammatory markers, or requirement for treatment with systemic glucocorticoids AND tried Actemra or Kineret. SJIA renewal approve if it patient was already started on Ilaris and the pt had a response (e.g. resolution of fever, improvement in limitations of motion, less joint pain or tenderness, decreased duration of morning stiffness or fatigue, improved function or ADLs, reduced dosage of CS) and the pt is continuing therapy to maintain response/remission.

IMBRUVICA

Products Affected

- Imbruvica

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For patients with mantle cell lymphoma (MCL)-history of prior treatment. For patients with chronic lymphoid leukemia (CLL)-one prior treatment or 17p chromosome deletion
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

INLYTA

Products Affected

- Inlyta

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients already started on Inlyta for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Advanced renal cell carcinoma, approve the patient has failed at least one prior systemic therapy (eg, Torisel, Avastin, Sutent, IFN-alpha, IL-2, Votrient, Nexavar).

IRESSA

Products Affected

- Iressa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	Metastatic NSCLC - The patient has epidermal growth factor receptor (EGFR) exon 19 deletions OR has exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

IVIG

Products Affected

- Gammagard Liquid
- Gamunex-C injection solution 1 gram/10 mL (10 %)

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for Plan Year.
Other Criteria	Part B versus D determination per CMS guidance to establish if drug used for PID in pts home.

JAKAFI

Products Affected

- Jakafi oral tablet 10 mg, 15 mg, 20 mg, 25 mg, 5 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients already started on Jakafi for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

JUXTAPID

Products Affected

- Juxtapid

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

KALYDECO

Products Affected

- Kalydeco

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

KEVEYIS

Products Affected

- Keveyis

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Patient with history of hypersensitivity to diclorphenamide or other sulfonamides, Patient on high dose aspirin, Patient with severe pulmonary disease, Patient with hepatic insufficiency
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a physician who specializes in the care of patients with primary periodic paralysis (e.g., muscle disease specialist, physiatrist).
Coverage Duration	Initial therapy - 2 months, Continuing therapy - plan year

PA Criteria	Criteria Details
Other Criteria	<p>Hyperkalemic Periodic Paralysis (HyperPP) and Related Variants: Patient has a confirmed diagnosis of primary hyperkalemic periodic paralysis by meeting at least ONE of the following criteria: Patient has had an increase from baseline in serum potassium concentration of greater than or equal to 1.5 mEq/L during a paralytic attack OR Patient has had a serum potassium concentration during a paralytic attack of greater than 5.0 mEq/L OR Patient has a family history of the condition OR Patient has a genetically confirmed skeletal muscle sodium channel mutation AND The prescribing physician has excluded other reasons for acquired hyperkalemia (e.g., drug abuse, renal and adrenal dysfunction) For Continuation of treatment a patient has decrease in the frequency or severity of paralytic attacks with treatment as determined by the prescribing physician. For Hypokalemic Periodic Paralysis (HypoPP) and Related Variants for Initiation of treatment: Patient has a confirmed diagnosis of primary hypokalemic periodic paralysis by meeting at least ONE of the following: Patient has had a serum potassium concentration of less than 3.5 mEq/L during a paralytic attack OR Patient has a family history of the condition OR Patient has a genetically confirmed skeletal muscle calcium or sodium channel mutation AND Patient has had improvements in paralysis attack symptoms with potassium intake. For Continuation of treatment: Patient has decrease in the frequency or severity of paralytic attacks with treatment as determined by the prescribing physician</p>

KORLYM

Products Affected

- Korlym

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

KUVAN

Products Affected

- Kuvan oral tablet, soluble

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Blood phenylalanine (Phe) levels. Pretreatment blood phenylalanine (Phe) levels greater than 10mg/dL if the patient is older than 12 years of age or greater than 6mg/dL if less than or equal to 12 years of age. Response to a therapeutic trial (greater than or equal to a 30% reduction in blood Phe levels) is required for long-term authorization.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 month initial, plan year on renewal
Other Criteria	Blood Phe levels should be checked after 1 week of therapy and periodically up to one month during a therapeutic trial.

LENVIMA

Products Affected

- Lenvima

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

LETAIRIS

Products Affected

- Letairis

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	NYHA class II or III symptoms. PAH been confirmed by right heart catheterization.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	UD or two appropriate contraceptive methods will be used for women of childbearing potential.

LEUKINE

Products Affected

- Leukine injection recon soln

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Administration within 24 hours preceding or following chemotherapy or radiotherapy, hypersensitivity to yeast-derived products. For prophylaxis of febrile neutropenia: use to increase the chemotherapy dose intensity or dose schedule above established regimens. For treatment of febrile neutropenia, when patient receives Neulasta during the current chemotherapy cycle. For AML only, excessive (greater than or equal to 10%) leukemic myeloid blasts in the bone marrow or peripheral blood.
Required Medical Information	For patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy: Leukine may be used for the prevention of chemotherapy-induced febrile neutropenia if the patient experienced febrile neutropenia with a prior chemotherapy cycle OR the patient is at risk of developing febrile neutropenia. Leukine is allowable for the treatment of febrile neutropenia in patients who have received prophylaxis with Leukine (or Neupogen) OR in patients at risk for infection-related complications.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A

LEUPROLIDE

Products Affected

- Eligard
- Lupron Depot
- Lupron Depot (3 Month)
- Lupron Depot (4 Month)
- Lupron Depot (6 Month)
- Lupron Depot-Ped intramuscular kit 11.25 mg, 15 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D but specific to the following drugs as follows: Prostate cancer (Lupron Depot [7.5 mg-1mo, 22.5 mg-3-mo, 30 mg-4-mo, 45 mg-6-mo] OR Eligard [7.5 mg-1-mo, 22.5mg-3-mo, 30 mg-4-mo, 45 mg-6-mo]), Endometriosis (Lupron Depot [3.75 mg-1-mo, 11.25 mg-3-mo]), Uterine leiomyomata (Lupron Depot [3.75 mg-1-mo, 11.25 mg-3-mo]), Treatment of central precocious puberty (Lupron Depot Ped [11.25 mg-1-mo, 15 mg-1-mo]). Ovarian cancer (Lupron Depot [7.5 mg-1-mo]). Breast cancer (Lupron Depot [3.75 mg-1-mo, 11.25 mg-3-mo]). Prophylaxis or treatment of uterine bleeding in premenopausal women with hematologic malignancy or prior to bone marrow/stem cell transplantation (BMT/SCT) (Lupron Depot [3.75 mg-1-mo, 7.5 mg-1-mo]).
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	For abnrml uterine bleeding, uterine leiomyomata,endometriosis-6 mo.All other=Plan Year
Other Criteria	N/A

LIDOCAINE PATCH

Products Affected

- lidocaine topical adhesive patch,medicated

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus diabetic neuropathic pain.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

LONSURF

Products Affected

- Lonsurf

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Treatment-naïve patients
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan year
Other Criteria	For Metastatic colorectal cancer, patient must have previously been treated with a fluoropyrimidine (e.g., capecitabine, 5-FU) AND oxaliplatin AND irinotecan AND an anti-VEGF therapy And if RAS wild type, an anti-EGFR therapy.

LYNPARZA

Products Affected

- Lynparza

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

MEKINIST

Products Affected

- Mekinist

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Documentation of the detected BRAFV600E or BRAFV600K mutation
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

NAMENDA

Products Affected

- memantine
- Namenda
- Namenda Titration Pak
- Namenda XR

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

NATPARA

Products Affected

- Natpara

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Hypoparathyroidism caused by calcium-sensing receptor mutations. Patients with acute post-surgical hypoparathyroidism.
Required Medical Information	Serum calcium level
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	For diagnosis of hypocalcemia in patients with hypoparathyroidism, documentation required to show hypocalcemia is not corrected by calcium supplements and active forms of vitamin D alone.

NEUPOGEN

Products Affected

- Neupogen

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Administration within 24 hours preceding or following chemotherapy or radiotherapy, E coli hypersensitivity. For prophylaxis of febrile neutropenia: use to increase the chemotherapy dose intensity or dose schedule beyond established regimen. For treatment of febrile neutropenia, when patient receives Neulasta during the current chemotherapy cycle.
Required Medical Information	For patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy: Neupogen may be used for the prevention of chemotherapy-induced febrile neutropenia if the patient experienced febrile neutropenia with a prior chemotherapy cycle OR the patient is at risk of developing febrile neutropenia. Neupogen is allowable for the treatment of febrile neutropenia in patients who have received prophylaxis with Neupogen (or Leukine) OR in patients at risk for infection-related complications.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A

NEUPRO

Products Affected

- Neupro

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	N/A

NEXAVAR

Products Affected

- Nexavar

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Combination with carboplatin and paclitaxel in patients with squamous cell lung cancer
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Oncologist
Coverage Duration	Plan Year
Other Criteria	N/A

NINLARO

Products Affected

- Ninlaro

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Previous therapies tried and failed, baseline CBC
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	For multiple myeloma, patient has received at least one prior therapy AND will be used in combination with lenalidomide and dexamethasone.

NORTHERA

Products Affected

- Northera

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial 4 weeks, renewal 6 months
Other Criteria	N/A

NUPLAZID

Products Affected

- Nuplazid

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

NUVIGIL/PROVIGIL

Products Affected

- modafinil

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients must be greater than or equal to 17 years of age.
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	Excessive sleepiness due to SWSD if the patient is working at least 5 overnight shifts per month.

OCTREOTIDE

Products Affected

- octreotide acetate injection solution 1,000 mcg/mL, 500 mcg/mL
- octreotide acetate injection solution 100 mcg/mL, 200 mcg/mL, 50 mcg/mL

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ODOMZO

Products Affected

- Odomzo

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan year
Other Criteria	For locally advanced basal cell carcinoma (BCC) has recurred following surgery or radiation therapy or if the patient is not a candidate for surgery and the patient is not a candidate for radiation therapy, according to the prescribing physician.

OFEV

Products Affected

- Ofev

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Combination use with pirfenidone
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in combination with a pulmonologist
Coverage Duration	Plan Year
Other Criteria	IPF baseline - must have FVC greater than or equal to 50 percent of the predicted value AND IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP.

ONCASPAR

Products Affected

- Oncaspar

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ONFI

Products Affected

- Onfi oral suspension
- Onfi oral tablet 10 mg, 20 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	The patient will receive Onfi for the treatment of seizures associated with Lennox-Gastaut syndrome.
Age Restrictions	2 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

OPDIVO

Products Affected

- Opdivo intravenous solution 40 mg/4 mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

OPSUMIT

Products Affected

- Opsumit

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	PAH WHO group, right heart catheterization
Age Restrictions	N/A
Prescriber Restrictions	PAH - must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	Plan Year
Other Criteria	Pulmonary arterial hypertension (PAH) WHO Group 1 patients not currently on Opsumit or another agent indicated for WHO Group 1 PAH are required to have had a right-heart catheterization to confirm the diagnosis of PAH to ensure appropriate medical assessment. PAH WHO Group 1 patients currently on Opsumit or another agent indicated for WHO Group 1 PAH may continue therapy without confirmation of a right-heart catheterization. For patients not currently on Opsumit with confirmed diagnosis of PAH, approval will be given after a trial of Letairis, unless contraindicated.

PEGINTRON

Products Affected

- PegIntron
- PegIntron Redipen

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Decompensated liver disease. Autoimmune hepatitis. Concomitant administration of didanosine with ribavirin in patients coinfectd with HIV.
Required Medical Information	HCV: Prior to initiating therapy, detectable levels of HCV RNA in the serum.
Age Restrictions	N/A
Prescriber Restrictions	ID specialist, Gastroenterologist, Oncologist
Coverage Duration	Plan Year
Other Criteria	Monitor for evidence of depression.

PENICILLAMINE

Products Affected

- Depen Titratabs

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	N/A

PHENOXYBENZAMINE

Products Affected

- phenoxybenzamine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

POMALYST

Products Affected

- Pomalyst

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	For active myeloma, patient meets the following: 1) Pomalyst is used after at least two prior therapies or as salvage therapy. 2) Pomalyst may be used with dexamethasone. For female patients of childbearing potential, pregnancy is excluded by 2 negative serum or urine pregnancy tests. For all patients, complete blood counts are monitored for hematologic toxicity while receiving Pomalyst.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Male and female patients of child-bearing potential should be instructed on the importance of proper utilization of appropriate contraceptive methods for Pomalyst use. Patients should be monitored for signs and symptoms of thromboembolism.

POTIGA

Products Affected

- Potiga

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

PRALUENT

Products Affected

- Praluent Pen subcutaneous pen injector 150 mg/mL, 75 mg/mL
- Praluent Syringe subcutaneous syringe 150 mg/mL, 75 mg/mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of Praluent with Repatha, Juxtapid or Kynamro.
Required Medical Information	Current LDL-C (within the past 30 days), prior therapies tried, medication adverse event history
Age Restrictions	18 years of age and older.
Prescriber Restrictions	Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders
Coverage Duration	Initial Prior Authorization: 6 months, Continuation of Therapy: Plan Year

PA Criteria	Criteria Details
Other Criteria	<p>Hyperlipidemia in pts w/ (ASCVD) apprv if the pt has a curr LDL-C lvl of grtr or eq to 70 mg/dL w/in the past 30 ds (after tx with antihyperlipidemic agnts but prior to PCSK9 inh tx such as Praluent or Repatha) AND the pt has had one of the following conds or dxs: prev MI,OR has a hx of an acute coronary syndrome, OR The pt has a dx of angina (stable or unstable) ,OR The pt has a past hx of stroke or TIA, OR The pt has PAD, The pt has undergone a coronary or other arterial revascularization procedure AND The pt has tried 1 high-intensity statin tx (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks AND the LDL-C lvl remains equal or more than 70 mg/dL unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Praluent tx. Heterozygous Familial Hypercholesterolemia apprve if the pt has a curnt LDL-C lvl eq or more than 100 mg/dL w/in the past 30 days, AND the pts dx of HeFH is def by WHO/Dutch Lipid grp criteria OR Simon-Broome Criteria OR genetic testing, AND The pt has tried 1 high-intensity statin txs (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks, AND the LDL-C lvl remains eq or more than 100 mg/dL, unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Praluent tx.</p>

PROCrit

Products Affected

- Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D worded as anemia associated with chronic renal failure (CRF), including patients on dialysis and not on dialysis, and worded as anemia secondary to myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma, and lymphocytic leukemia, . Plus anemia in patients with HIV who are receiving zidovudine. Anemic patients (Hb of 13.0 g/dL or less) at high risk for perioperative transfusions (secondary to significant, anticipated blood loss and are scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions). Additional off-label coverage is provided for Anemia due to myelodysplastic syndrome (MDS), Anemia associated with use of ribavirin therapy for hepatitis C (in combination with interferon or pegylated interferon alfa 2a/2b products with or without the direct-acting antiviral agents Victrelis or Incivek), and Anemia in HIV-infected patients.
Exclusion Criteria	N/A
Required Medical Information	CRF anemia in patients on and not on dialysis.Hemoglobin (Hb) of less than 10.0 g/dL for adults or less than or equal to 11 g/dL for children to start.Hb less than or equal to 11.5 g/dL for adults or 12 g/dL or less for children. Anemia w/myelosuppressive chemotx.pt must be currently receiving myelosuppressive chemo and Hb 10.0 g/dL or less to start.Hb less than or equal to 12.0 g/dL . MDS, approve if Hb is 10 g/dL. Surgical pts to reduce RBC transfusions - pt is unwilling or unable to donate autologous blood prior to surgery
Age Restrictions	MDS anemia/HepC anemia = 18 years of age and older
Prescriber Restrictions	MDS anemia, prescribed by or in consultation with, a hematologist or oncologist. Hep C anemia, prescribed by or in consultation with hepatologist, gastroenterologist or infectious disease physician who specializes in the management of hepatitis C.
Coverage Duration	Anemia w/myelosuppress = 4 mos.Transfus=1 mo.Other= 6mo. HIV + zidovudine = 4 mo

Updated: 09/2016

H0811_GN134_Web Prior Auth_Approved

PA Criteria	Criteria Details
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance to establish if the drug prescribed is to be used for an end-stage renal disease (ESRD)-related condition.

PROMACTA

Products Affected

- Promacta oral tablet 12.5 mg, 25 mg, 50 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Thrombocytopenia due to hepatitis C virus (HCV)-related cirrhosis.
Exclusion Criteria	Use in the management of thrombocytopenia in myelodysplastic syndrome (MDS). Use in combination with Nplate for treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia purpura.
Required Medical Information	Cause of thrombocytopenia. Thrombocytopenia due to HCV-related cirrhosis, platelet counts.
Age Restrictions	N/A
Prescriber Restrictions	Treatment of thrombocytopenia due to chronic immune (idiopathic) thrombocytopenic purpura (ITP), approve if prescribed by, or after consultation with, a hematologist. Treatment of thrombocytopenia due to HCV-related cirrhosis, approve if prescribed by, or after consultation with, either a gastroenterologist, a hepatologist, or a physician who specializes in infectious disease.
Coverage Duration	Plan Year
Other Criteria	Thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia purpura, approve if the patient has tried corticosteroids or IVIG or has undergone a splenectomy. Treatment of thrombocytopenia due to HCV-related cirrhosis, approve to allow for initiation of antiviral therapy if the patient has low platelet counts (eg, less than 75,000 mm3) and the patient has chronic HCV infection and is a candidate for hepatitis C therapy .

QUININE

Products Affected

- quinine sulfate

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	N/A

RAVICTI

Products Affected

- Ravicti

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

REBIF

Products Affected

- Rebif (with albumin)
- Rebif Rebidose subcutaneous pen injector 22 mcg/0.5 mL, 44 mcg/0.5 mL, 8.8mcg/0.2mL-22 mcg/0.5mL (6)
- Rebif Titration Pack

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

REMICADE

Products Affected

- Remicade

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Active infection (including TB), concurrent use with other biologics, unstable moderate to severe HF (NYHA Functional Class III/IV).
Required Medical Information	Screening for latent TB infection and assessment for Hep B risk. For positive latent TB, patient must have completed treatment or is currently receiving treatment for LTBI. HBV infection ruled out or treatment initiated for positive infection. Rheumatoid arthritis - An inadequate response or intolerance to Enbrel or Humira and one of the following: 1) inadequate response to methotrexate (MTX), 2) inadequate response to another nonbiologic DMARD (e.g., leflunomide, hydroxychloroquine, sulfasalazine) if contraindicated or intolerant to MTX, 3) intolerance or contraindication to 2 nonbiologic DMARDs. Psoriatic arthritis with predominantly peripheral symptoms - Must meet both of the following: 1) have an inadequate response or intolerance to either Enbrel or Humira, and 2) have an inadequate response to at least an 8-week maximum tolerated dose trial of at least 1 nonbiologic DMARD unless contraindicated or intolerant to such therapy. For plaque psoriasis - More than 10% BSA affected or has crucial body areas (e.g., feet, hands, face) affected. An inadequate response to at least a 60-day trial of 2 conventional therapies (e.g., phototherapy, calcipotriene, MTX, acitretin) unless contraindicated or intolerant to such therapies. Crohn's disease - Must meet both of the following: 1) have an inadequate response to at least a 60-day trial of 1 conventional therapy (e.g., corticosteroids, sulfasalazine, azathioprine, mesalamine) unless contraindicated or intolerant to such therapy, and 2) have an inadequate response or intolerance to either Humira or Cimzia. Ulcerative colitis - An inadequate response to at least a 60-day trial of 2 conventional therapies (e.g., corticosteroids, mesalamine) unless contraindicated or intolerant to such therapies.
Age Restrictions	For plaque psoriasis, patient must be 18 years of age and older.
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months for Crohn's disease and UC, plan year for all others. Renewal: plan year

Updated: 09/2016
H0811_GN134_Web Prior Auth_Approved

PA Criteria	Criteria Details
Other Criteria	For continuation of therapy, patient's condition must have improved or stabilized.

REPATHA

Products Affected

- Repatha SureClick
- Repatha Syringe

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of Repatha with Praluent, Juxtapid or Kynamro
Required Medical Information	Current LDL-C (within the past 30 days), prior therapies tried, medication adverse event history
Age Restrictions	ASCVD/HeFH - 18 yo and older, HoFH 13 yo and older.
Prescriber Restrictions	Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders
Coverage Duration	Initial Prior Authorization: 6 months, Continuation of Therapy: Plan Year

PA Criteria	Criteria Details
Other Criteria	<p>Hyperlipidemia in pts w/ (ASCVD) apprv if the pt has a curr LDL-C lvl of grtr or eq to 70 mg/dL w/in the past 30 ds (after tx with antihyperlipidemic agnts but prior to PCSK9 inh tx such as Praluent or Repatha) AND the pt has had one of the following conds or dxs: prev MI,OR has a hx of an acute coronary syndrome, OR The pt has a dx of angina (stable or unstable) ,OR The pt has a past hx of stroke or TIA, OR The pt has PAD, The pt has undergone a coronary or other arterial revascularization procedure AND The pt has tried 1 high-intensity statin tx (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks AND the LDL-C lvl remains equal or more than 70 mg/dL unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Repatha tx. Heterozygous Familial Hypercholesterolemia apprve if the pt has a curnt LDL-C lvl eq or more than 100 mg/dL w/in the past 30 days, AND the pts dx of HeFH is def by WHO/Dutch Lipid grp criteria OR Simon-Broome Criteria OR genetic testing, AND The pt has tried 1 high-intensity statin txs (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks, AND the LDL-C lvl remains eq or more than 100 mg/dL, unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Repatha tx. HoFH - approve if meets all of the following has one of the following genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus AND LDL-C lvl grtr or eq to 100 mg/dL within the past 30 ds AND tried 1 high-intensity statin therapystatin tx (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks AND the LDL-C lvl remains equal or more than 100 mg/dL unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Repatha tx.</p>

REVATIO

Products Affected

- sildenafil oral

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Nitrate therapy
Required Medical Information	Diagnosis of pulmonary arterial hypertension (PAH), (WHO Group 1). PAH been confirmed by right heart catheterization. If patient is an infant, PAH diagnosed by Doppler echocardiogram.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

REVLIMID

Products Affected

- Revlimid

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	For active myeloma patient meets one of the following: 1) Revlimid is used in combination with dexamethasone. 2) Revlimid is used as maintenance monotherapy following response to either stem cell transplant or primary induction therapy. For mantle cell lymphoma (MCL): Revlimid is used after 2 prior therapies, 1 of which is bortezomib. For Low or Intermediate-1 Risk myelodysplastic syndrome (MDS): for those with 5q deletion, patients should have transfusion-dependent anemia or symptomatic anemia with clinically significant cytopenias. For those with non-5q deletion MDS and symptomatic anemia, patients should have failed to respond to epoetin alfa or darbepoetin or have a pretreatment serum erythropoietin levels greater than 500 mU/mL and a low probability of response to immunosuppressive therapy. For female patients of childbearing potential, pregnancy is excluded by 2 negative serum or urine pregnancy tests. For all patients, complete blood counts are monitored for hematologic toxicity while receiving Revlimid.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Male and female patients of child-bearing potential should be instructed on the importance of proper utilization of appropriate contraceptive methods for Revlimid use. Patients should be monitored for signs and symptoms of thromboembolism.

RIBAVIRIN

Products Affected

- ribavirin oral capsule
- ribavirin oral tablet 200 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Hemoglobin less than 10 g/dL. Hemoglobinopathy. History of pre-existing heart disease. Creatinine clearance less than 50 mL/minute and unwilling to use modified dose of ribavirin. Pregnancy (self or partner). Unwilling to use effective contraception. Coadministration with didanosine in HIV coinfecting patients.
Required Medical Information	Prior to initiating therapy, detectable levels of HCV RNA in the serum. Must use in combination with Harvoni, interferon, Viekira, or Sovaldi. Cirrhosis documented by FibroScan, liver biopsy, or radiological imaging
Age Restrictions	N/A
Prescriber Restrictions	ID specialist, gastroenterologist, or oncologist
Coverage Duration	12 wks, 24 wks, or 48 wks as specified in Other Criteria.
Other Criteria	Adults: 12wk: geno 1a+no cirr-w/Viekira, geno 2-w/Sovaldi, geno 3, 4, 5, 6-w/PEG/Sovaldi, Gen 1/4 post-transplant +Harvoni. 16wk: geno 2 w/cirr + Sovaldi. 24wk: geno 1a+cirr-w/Viekira, geno 3, 4-w/Sovaldi. Children: 48 wk all genotypes

RITUXAN

Products Affected

- Rituxan

PA Criteria	Criteria Details
Covered Uses	All medically-accepted indications not otherwise excluded from Part D. Patients already started on Rituxan for a Covered Use.
Exclusion Criteria	Concurrent use with a biologic agent (TNF alpha antagonists (eg, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), or anakinra, abatacept, tocilizumab or tofacitinib.
Required Medical Information	N/A
Age Restrictions	RA, adults.
Prescriber Restrictions	Adult with RA (initial course). Prescribed by a rheumatologist or in consultation with a rheumatologist.
Coverage Duration	RA, 1mo. Othr= Plan Year.
Other Criteria	Adult with RA (initial course), approve if Rituxan is prescribed in combination with methotrexate or another traditional DMARD (eg, leflunomide or sulfasalazine) unless the patient has been shown to be intolerant or has a contraindication to one or more traditional DMARDs AND the patient has tried one of certolizumab pegol, etanercept, adalimumab, infliximab, golimumab (ie, a TNF antagonist) OR if the patient has not yet tried a TNF antagonist, the patient must have a trial with etanercept or adalimumab.

SABRIL

Products Affected

- Sabril

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Patients with or at high risk of vision loss (except patients who have blindness). Patients using other medications associated with serious adverse ophthalmic effects such as retinopathy or glaucoma.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Infantile spasms: initial 4 wks, reauth 6 mths. CPS: initial 3 mths, reauth to plan year
Other Criteria	N/A

SAMSCA

Products Affected

- Samsca oral tablet 15 mg, 30 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Up to 30 days
Other Criteria	N/A

SANDOSTATIN LAR

Products Affected

- Sandostatin LAR Depot intramuscular suspension, extended rel recon

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Patient received initial treatment with Sandostatin Injection (not the Depot form) for at least 2 weeks and treatment with Sandostatin Injection was effective and tolerable.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

SIGNIFOR

Products Affected

- Signifor

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Signifor is being used.
Age Restrictions	Cushing's, 18 years of age and older.
Prescriber Restrictions	Initial course, prescribed by or in consultation with an endocrinologist.
Coverage Duration	Initial therapy, approve for 3 months. Continuation therapy, approve for the plan year.
Other Criteria	Cushing's disease, approve if according to the prescribing physician the patient is not a candidate for surgery or surgery has not been curative. Patients who have already been started on Signifor for Cushing's disease will be approved if the patient has had a response, as determined by the prescribing physician and the patient is continuing therapy to maintain response.

SOVALDI

Products Affected

- Sovaldi

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prior to initiating therapy, detectable levels of HCV RNA in the serum. Must be used in combination with interferon+ribavirin, ribavirin, or Olysio. Cirrhosis documented by FibroScan, liver biopsy, or radiological imaging
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation w/ GI, hepatologist, ID, or a liver transplant MD
Coverage Duration	12 wks, 24 wks, or 48 wks as specified in Other Criteria.
Other Criteria	Geno 1-Patient must have tried Viekira or Harvoni. Geno 2,3,4,5,6 - prescribed in combo with RBV. Coverage duration: 12wk: geno 1+no cirr, geno 2 naïve-w/RBV, geno 2 prior tx fail w/PEG/RBV or SOV/RBV-w/PEG/RBV, geno 3 naïve-w/PEG/RBV, geno 3 prior tx fail w/PEG/RBV or SOV/RBV-w/PEG/RBV, geno 4 naïve w/PEG/RBV, geno 4 prior tx fail w/ PEG/RBV -w/PEG/RB , geno 5/6 naïve/exp - w/PEG/RBV. 16wk: geno 2 naïve+cirr w/RBV. 24wk: geno 1+cirr, geno 2 prior tx fail w/PEG/RBV (16 weeks if requested by prescriber)-w/RBV, post-liver transplant +cirr w/RBV, geno 3 naïve-w/RBV, post-liver transplant + cirr w/RBV, geno 4 naïve w/ RBV, geno 4 prior tx fail w/ PEG/RBV -w/RBV. 48wk: Others

SPRYCEL

Products Affected

- Sprycel oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Acute lymphoblastic leukemia (ALL) and newly diagnosed chronic myeloid leukemia (CML) must be positive for the Philadelphia chromosome or BCR-ABL gene. For CML, patient meets one of the following: 1) newly diagnosed in chronic phase, 2) resistance or intolerance to imatinib, or 3) relapse after stem cell transplant. For ALL, resistance or intolerance to prior therapy.
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

STIVARGA

Products Affected

- Stivarga

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Stivarga for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Stivarga is being used. For metastatic colorectal cancer (CRC) and gastrointestinal stromal tumors (GIST), prior therapies tried. For metastatic CRC, KRAS mutation status.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For metastatic CRC with KRAS mutation, patient must have previously been treated with each of the following for approval: a fluoropyrimidine (eg, Xeloda, 5-FU), oxaliplatin, irinotecan, anti-VEGF therapy (eg, Avastin, Zaltrap). For metastatic CRC with no detected KRAS mutations (ie, KRAS wild-type), patient must have previously been treated with each of the following for approval: a fluoropyrimidine (eg, Xeloda, 5-FU), oxaliplatin, irinotecan, anti-VEGF therapy (eg, Avastin, Zaltrap), anti-EGFR therapy (eg, Eribitux, Vectibix). For GIST, patient must have previously been treated with imatinib (Gleevec) and sunitinib (Sutent).

SUTENT

Products Affected

- Sutent

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Clinical manifestations of congestive heart failure.
Required Medical Information	For gastrointestinal stromal tumor (GIST), disease progression while on an at least 30-day regimen of Gleevec or intolerance to Gleevec is required. LFT monitoring at initiation of therapy and throughout treatment.
Age Restrictions	N/A
Prescriber Restrictions	Oncologist
Coverage Duration	Plan Year
Other Criteria	Therapy will be interrupted for serious hepatic adverse events and discontinued if serious hepatic adverse events do not resolve.

SYLATRON

Products Affected

- Sylatron

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

SYNAGIS

Products Affected

- Synagis intramuscular solution 50 mg/0.5 mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Prophylaxis of Respiratory Syncytial Virus (RSV): One of the following: (criteria 1) all of the following: Infant is less than 24 months of age, infant has chronic lung disease (CLD), infant required medical therapy (supplemental oxygen, bronchodilator, diuretic or corticosteroid therapy) within 6 months prior to the start of RSV season, (criteria 2) all of the following: infant was born at 28 weeks of gestation or earlier, infant does not have chronic lung disease (CLD), and infant was less than 12 months of age at the start of RSV season, (criteria 3) all of the following: infant was born at 29 to 32 weeks of gestation (ie, 31 weeks, 6 days or less), infant does not have chronic lung disease (CLD), and infant was less than 6 months of age at the start of RSV season. (criteria 4): infant was born at 32 to less than 35 weeks of gestation (ie, between 32 weeks, 0 days through 34 weeks, 6 days), infant does not have CLD, infant was less than 3 months of age at the start of the RSV season, and infant has one of the following risk factors: (1) Child care attendance defined as a home or facility in which care is provided for any number of infants or toddlers OR (2) Infant has a sibling younger than 5 years of age, (criteria 5) both of the following: Infants and children 24 months of age and younger, or Infant or child has one of the following: (1) Congenital abnormalities of the airways, or (2) Neuromuscular condition that compromises handling of respiratory secretions, (criteria 6) both of the following: Infants and children 24 months of age or younger, or infant or child has hemodynamically significant cyanotic or acyanotic congenital heart disease (CHD) (eg, receiving medication to control congestive heart failure, moderate to severe pulmonary hypertension), (criteria 7) both of the following: Infants and children 24 months of age and younger, infant or child has severe immunodeficiency (eg, severe combined immunodeficiency or advanced AIDS) (off label).</p>
Age Restrictions	N/A
Prescriber Restrictions	N/A

PA Criteria	Criteria Details
Coverage Duration	5 months
Other Criteria	Synagis will not be approved for the following conditions unless one of the required criteria is met: 1) Infants and children with hemodynamically insignificant heart disease (eg, secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus), 2) Infants with lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure, 3) Infants with mild cardiomyopathy who are not receiving medical therapy for the condition.

TAFINLAR

Products Affected

- Tafinlar

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Documentation of the detected BRAF V600E or V600K mutations
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

TAGRISSO

Products Affected

- Tagrisso

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus patients already started on Tagrisso for a covered use.
Exclusion Criteria	EGFR tyrosine kinase inhibitor treatment naive patients
Required Medical Information	Confirmed T790M mutation-positive NSCLC as detected by an FDA approved test and Prior therapies tried
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	The patient has metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC as detected by an FDA approved test AND The patient has progressed on or after one of Tarceva (erlotinib tablets), Iressa (gefitinib tablets), or Gilotrif (afatinib tablets) therapy.

TARCEVA

Products Affected

- Tarceva oral tablet 100 mg, 150 mg, 25 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For 1st line therapy of locally advanced or metastatic NSCLC, patient should have a known active EGFR exon 19 deletions or exon 21 substitution mutation or amplification of the EGFR gene.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

TARGRETIN

Products Affected

- bexarotene
- Targretin oral

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	For capsules, patient meets one of the following: 1) cutaneous T cell lymphoma (includes mycosis fungoides [MF] and Sezary syndrome [SS]) refractory to prior systemic therapy, 2) advanced-stage MF/Sezary syndrome, 3) early-stage MF refractory/progressive to skin-directed therapy, or 4) early-stage MF with blood involvement or folliculotropic/large cell transformation.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Patient has been instructed on the importance of and proper utilization of contraception.

TASIGNA

Products Affected

- Tasigna

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Long QT syndrome, uncorrected electrolyte disorders (hypokalemia, hypomagnesemia).
Required Medical Information	ECG obtained at baseline, 7-10 days after initiation of therapy and periodically throughout therapy. Newly diagnosed chronic myeloid leukemia (CML) must be positive for the Philadelphia chromosome or BCR-ABL gene. For CML, patient meets one of the following: 1) newly diagnosed in chronic phase, 2) resistance to imatinib, 3) intolerance/toxicity to imatinib or dasatinib, or 4) relapse after stem cell transplant.
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Patient has been instructed to avoid eating food 2 hours before and 1 hour after taking Tasigna. Concomitant use of drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided.

TECENTRIQ

Products Affected

- Tecentriq

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	N/A

THALOMID

Products Affected

- Thalomid

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	For active myeloma, patient meets one of the following: 1) Thalomid is used as salvage or palliative therapy. 2) Thalomid is used for newly diagnosed disease or as primary induction therapy in combination with dexamethasone or in combination with melphalan and prednisone in nontransplant candidates. 3) Thalomid is used as maintenance monotherapy following response to either stem cell transplant or primary induction therapy. For female patients of childbearing potential, pregnancy is excluded by a negative pregnancy test.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Patients are monitored for signs and symptoms of thromboembolism. Male and female patients of child-bearing potential are instructed on the importance of proper utilization of appropriate contraceptive methods.

THIORIDAZINE

Products Affected

- thioridazine

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

THIOTEPA

Products Affected

- thiotepa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

TIRF MEDICATIONS

Products Affected

- fentanyl citrate buccal lozenge on a handle
1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For breakthrough pain in patients with cancer if patient is unable to swallow, has dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting OR patient is unable to take 2 other short-acting narcotics (eg, oxycodone, morphine sulfate, hydromorphone, etc) secondary to allergy or severe adverse events AND patient is on or will be on a long-acting narcotic (eg, Duragesic), or the patient is on intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotics (eg, morphine sulfate, hydromorphone, fentanyl citrate).

TRETINOIN

Products Affected

- adapalene topical cream
- adapalene topical gel
- tretinoin microspheres topical gel with pump
- tretinoin topical

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Coverage is not provided for cosmetic use.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

TYKERB

Products Affected

- Tykerb

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Liver function tests must be monitored at baseline and every four to six weeks during therapy and as clinically indicated. In patients with severe hepatic impairment, Tykerb is used at a reduced dose.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

TYSABRI

Products Affected

- Tysabri

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Tysabri for a Covered Use.
Exclusion Criteria	Concurrent use of another immunomodulator (eg, Rebif, Betaseron, Extavia, Copaxone or Avonex or Aubagio), Tecfidera, or fingolimod (Gilenya) or an immunosuppressant such as mitoxantrone, cyclophosphamide, rituximab (Rituxan), alemtuzumab (Campath), azathioprine, MTX, or mycophenolate mofetil in multiple sclerosis (MS) patients. Concurrent use with immunosuppressants (eg, 6-mercaptopurine, azathioprine, cyclosporine, methotrexate) or tumor necrosis factor (TNF) alfa inhibitors (eg, infliximab, adalimumab, certolizumab pegol) in Crohn's disease (CD) patients. Per warning and precautions, coverage is not provided for immune compromised patients with MS or CD.
Required Medical Information	Adults with MS. Patient has a relapsing form of MS (relapsing forms of MS are relapsing remitting [RRMS], secondary progressive [SPMS] with relapses, and progressive relapsing [PRMS]). Adults with CD. Patient has moderately to severely active CD with evidence of inflammation (eg, elevated C-reactive protein).
Age Restrictions	Adults
Prescriber Restrictions	MS. Prescribed by, or in consultation with , a neurologist or physician who specializes in the treatment of MS.CD. Prescribed by or in consultation with a gastroenterologist.
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	<p>Adults with a relapsing form of MS. Patient has had an inadequate response to, or is unable to tolerate, therapy with at least one of the following MS medications: interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), glatiramer acetate (Copaxone), fingolimod (Gilenya), Tecfidera, or Aubagio OR the patient has highly active or aggressive disease according to the prescribing physician. Adults with CD. Patient has moderately to severely active CD with evidence of inflammation (eg, elevated C-reactive protein) and patient has tried two TNF antagonists for CD for at least 2 months each, adalimumab, certolizumab pegol, or infliximab, and had an inadequate response or was intolerant to the TNF antagonists.</p>

VENCLEXTA

Products Affected

- Venclexta

- Venclexta Starting Pack

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapy, 17p deletion status
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	CLL - approve if the patient has 17p deletion and has tried one prior therapy.

VIEKIRA

Products Affected

- Viekira Pak

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent treatment with interferon, Sovaldi, Olysio, or Harvoni
Required Medical Information	Genotype and subtype
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation w/ GI, hepatologist, ID, or a liver transplant MD
Coverage Duration	24 wks G1a w cirrh and prior null response to HVC therapy, Rec HCV Post-Liver Trans, 12 wks others
Other Criteria	Geno 1a w/ or w/o cirrhosis-prescribed in combination with RBV. Liver transplant recipients with normal hepatic function and metavir score less than 2-prescribed in combination with RBV.

VIMPAT

Products Affected

- Vimpat intravenous
- Vimpat oral solution
- Vimpat oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	A. The patient will receive Vimpat as an adjunctive anticonvulsant for the treatment of partial onset seizures. B. The patient had a previous or present trial/failure/contraindication to two or more of the following: carbamazepine, divalproex, ethosuximide, ethotoin, gabapentin, lamotrigine, levetiracetam, methsuximide, oxcarbazepine, phenytoin, phenobarbital, pregabalin, rufinamide, tiagabine, topiramate, valproic acid or zonisamide.
Age Restrictions	17 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

VOTRIENT

Products Affected

- Votrient

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Alanine transaminase (ALT) greater than 3 times the upper limit of normal (ULN) and bilirubin greater than 2 times the ULN.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Oncologist
Coverage Duration	Plan Year
Other Criteria	N/A

XALKORI

Products Affected

- Xalkori

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients with non-small cell lung cancer (NSCLC) already started on crizotinib.
Exclusion Criteria	N/A
Required Medical Information	For the FDA-approved indication of NSCLC for patients new to therapy, ALK status required.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	NSCLC, patient new to therapy must be ALK-positive for approval.

XENAZINE

Products Affected

- tetrabenazine
- Xenazine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Tardive dyskinesia (TD). Tourette syndrome and related tic disorders. Hyperkinetic dystonia. Hemiballism.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	For treatment of chorea associated with Huntington's disease, Tourette syndrome or related tic disorders, hyperkinetic dystonia, or hemiballism, Xenazine or tetrabenazine must be prescribed by or after consultation with a neurologist. For TD, Xenazine or tetrabenazine must be prescribed by or after consultation with a neurologist or psychiatrist.
Coverage Duration	Plan Year
Other Criteria	N/A

XOLAIR

Products Affected

- Xolair

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For IgE-mediated allergic asthma: pre-treatment serum IgE and patient's weight
Age Restrictions	12 years of age and older
Prescriber Restrictions	Pulmonologist, allergist or immunologist
Coverage Duration	Plan Year
Other Criteria	To continue therapy, patients must demonstrate an improvement in asthma control with use of Xolair.

XTANDI

Products Affected

- Xtandi

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Xtandi for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Xtandi is being used. For metastatic castration-resistant prostate cancer, prior therapies tried.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For prostate cancer, patient must have metastatic, castration-resistant prostate cancer for approval.

YERVOY

Products Affected

- Yervoy intravenous solution 50 mg/10 mL (5 mg/mL)

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ZELBORAF

Products Affected

- Zelboraf

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients with melanoma already started on vemurafenib.
Exclusion Criteria	N/A
Required Medical Information	For the FDA-approved indication of melanoma, for patients new to therapy, BRAFV600E status required.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Melanoma, patient new to therapy must have BRAFV600E mutation for approval.

ZYDELIG

Products Affected

- Zydelig

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Documentation of AST/ALT less than 20 x ULN and Bilirubin less than 10 x ULN.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ZYKADIA

Products Affected

- Zykadia

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive, patient must have progressed or be intolerant to crizotinib for approval.

ZYVOX

Products Affected

- linezolid intravenous
- linezolid oral suspension for reconstitution
- linezolid oral tablet
- Zyvox intravenous parenteral solution 600 mg/300 mL
- Zyvox oral

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Culture and sensitivity and CBC within normal limits
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	28 days
Other Criteria	N/A

PART B VERSUS PART D

Products Affected

- Abelcet
- Abilify Maintena intramuscular suspension, extended rel recon 300 mg
- Abilify Maintena intramuscular suspension, extended rel syringe
- Abraxane
- acetylcysteine
- Actemra intravenous
- acyclovir sodium intravenous solution
- Adagen
- Adrucil intravenous solution 500 mg/10 mL
- A-Hydrocort
- albuterol sulfate inhalation solution for nebulization 0.63 mg/3 mL, 1.25 mg/3 mL, 2.5 mg /3 mL (0.083 %), 5 mg/mL
- Aldurazyme
- Alimta intravenous recon soln 500 mg
- AmBisome
- amifostine crystalline
- amikacin injection solution 500 mg/2 mL
- amino acids 15 %
- Aminosyn 8.5 %-electrolytes
- Aminosyn II 10 %
- Aminosyn II 15 %
- Aminosyn II 7 %
- Aminosyn II 8.5 %
- Aminosyn II 8.5 %-electrolytes
- Aminosyn M 3.5 %
- Aminosyn-HBC 7%
- Aminosyn-PF 10 %
- Aminosyn-PF 7 % (sulfite-free)
- Aminosyn-RF 5.2 %
- amiodarone intravenous solution
- amphotericin B
- ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg
- ampicillin-sulbactam injection recon soln 15 gram, 3 gram
- Aralast NP intravenous recon soln 500 mg
- Astagraf XL
- Avastin
- Avelox in NaCl (iso-osmotic)
- Azasan
- azathioprine
- azathioprine sodium
- azithromycin intravenous
- BACiiM
- bacitracin intramuscular
- BCG vaccine, live (PF)
- Beleodaq
- Benlysta
- benztropine injection
- Bicillin C-R
- BiCNU
- bleomycin injection recon soln 30 unit
- budesonide inhalation suspension for nebulization 0.25 mg/2 mL, 0.5 mg/2 mL, 1 mg/2 mL
- buprenorphine HCl injection syringe
- Busulfex
- calcitriol intravenous solution 1 mcg/mL
- calcitriol oral
- Cancidas
- Capastat
- carboplatin intravenous solution
- cefazolin in dextrose (iso-os) intravenous piggyback 1 gram/50 mL
- cefazolin injection recon soln 1 gram, 10 gram, 500 mg
- cefepime
- cefotaxime injection recon soln 1 gram, 2 gram, 500 mg
- cefoxitin
- cefoxitin in dextrose, iso-osm
- ceftazidime injection recon soln 1 gram, 2 gram
- ceftriaxone injection recon soln 10 gram, 250 mg, 500 mg
- ceftriaxone intravenous
- cefuroxime sodium injection recon soln 1.5 gram, 750 mg
- cefuroxime sodium intravenous

Updated: 09/2016

H0811_GN134_Web Prior Auth_Approved

- CellCept Intravenous
- CellCept oral suspension for reconstitution
- Cerezyme intravenous recon soln 400 unit
- chloramphenicol sod succinate
- cidofovir
- Cimzia Powder for Reconst
- ciprofloxacin lactate intravenous solution 400 mg/40 mL
- cisplatin
- cladribine
- clindamycin phosphate intravenous solution 600 mg/4 mL
- Clinimix 5%/D15W Sulfite Free
- Clinimix 5%/D25W sulfite-free
- Clinimix 2.75%/D5W Sulfit Free
- Clinimix 4.25%/D10W Sulf Free
- Clinimix 4.25%/D5W Sulfit Free
- Clinimix 4.25%-D20W sulf-free
- Clinimix 4.25%-D25W sulf-free
- Clinimix 5%-D20W(sulfite-free)
- Clinimix E 2.75%/D10W Sul Free
- Clinimix E 2.75%/D5W Sulf Free
- Clinimix E 4.25%/D10W Sul Free
- Clinimix E 4.25%/D25W Sul Free
- Clinimix E 4.25%/D5W Sulf Free
- Clinimix E 5%/D15W Sulfit Free
- Clinimix E 5%/D20W Sulfit Free
- Clinimix E 5%/D25W Sulfit Free
- colistin (colistimethate Na)
- cromolyn inhalation
- Cubicin
- cyclophosphamide oral capsule
- cyclosporine intravenous
- cyclosporine modified
- cyclosporine oral capsule
- cytarabine
- D2.5 %-0.45 % sodium chloride
- D5 % and 0.9 % sodium chloride
- D5 %-0.45 % sodium chloride
- dacarbazine intravenous recon soln 200 mg
- daunorubicin intravenous solution
- decitabine
- Delestrogen intramuscular oil 10 mg/mL
- Depo-Provera intramuscular solution
- dexamethasone sodium phosphate injection solution
- dexrazoxane HCl intravenous recon soln 250 mg
- dextrose 10 % and 0.2 % NaCl
- dextrose 10 % in water (D10W)
- dextrose 5 % in water (D5W) intravenous parenteral solution
- dextrose 5 %-lactated ringers
- dextrose 5%-0.2 % sod chloride
- dextrose 5%-0.3 % sod.chloride
- Dextrose With Sodium Chloride
- Dextrose-KCl-NaCl
- diltiazem HCl intravenous
- diphenhydramine HCl injection solution 50 mg/mL
- doxorubicin intravenous solution 50 mg/25 mL
- doxorubicin, peg-liposomal
- Doxy-100
- doxycycline hyclate intravenous
- dronabinol oral capsule 10 mg
- dronabinol oral capsule 2.5 mg, 5 mg
- Duramorph (PF) injection solution 0.5 mg/mL, 1 mg/mL
- Elaprase
- Elelyso
- Elitek
- Emend oral capsule
- Emend oral capsule,dose pack
- Engerix-B (PF) intramuscular syringe
- Engerix-B Pediatric (PF)
- Envarsus XR
- epirubicin intravenous solution 50 mg/25 mL
- Erythrocin intravenous recon soln 500 mg
- esomeprazole sodium
- estradiol valerate intramuscular oil 20 mg/mL, 40 mg/mL
- etoposide intravenous
- Fabrazyme intravenous recon soln 35 mg
- famotidine (PF)
- famotidine (PF)-NaCl (iso-os)
- Faslodex
- fluconazole in dextrose(iso-o) intravenous piggyback 400 mg/200 mL

Updated: 09/2016

H0811_GN134_Web Prior Auth_Approved

- fluconazole in NaCl (iso-osm) intravenous piggyback 200 mg/100 mL
- fludarabine intravenous recon soln
- fluorouracil intravenous solution 2.5 gram/50 mL
- fluphenazine decanoate
- fluphenazine HCl injection
- fomepizole
- fosphenytoin injection solution 100 mg PE/2 mL
- furosemide injection
- ganciclovir sodium
- gemcitabine intravenous recon soln 1 gram
- Gengraf oral capsule 100 mg, 25 mg
- Gengraf oral solution
- gentamicin in NaCl (iso-osm) intravenous piggyback 100 mg/100 mL
- gentamicin in NaCl (iso-osm) intravenous piggyback 80 mg/100 mL
- gentamicin injection solution 40 mg/mL
- Geodon intramuscular
- granisetron (PF) intravenous solution 100 mcg/mL
- granisetron HCl intravenous solution 1 mg/mL (1 mL)
- granisetron HCl oral
- haloperidol decanoate
- haloperidol lactate injection
- heparin (porcine) in 5 % dex intravenous parenteral solution 20,000 unit/500 mL (40 unit/mL), 25,000 unit/250 mL (100 unit/mL), 25,000 unit/500 mL (50 unit/mL)
- heparin (porcine) injection solution
- Hepatamine 8%
- Herceptin
- hydralazine injection
- hydromorphone (PF) injection solution 10 mg/mL
- hydroxyzine HCl intramuscular
- idarubicin
- ifosfamide intravenous recon soln 1 gram
- imipenem-cilastatin
- Increlex
- Intralipid intravenous emulsion 20 %, 30 %
- Intron A injection recon soln
- Intron A injection solution 6 million unit/mL
- Invanz injection
- Invega Sustenna
- Invega Trinza
- Ionosol-B in D5W
- Ionosol-MB in D5W
- ipratropium bromide inhalation
- ipratropium-albuterol
- irinotecan intravenous solution 100 mg/5 mL
- Istodax
- Kadcylla intravenous recon soln 100 mg
- Keytruda
- labetalol intravenous solution
- leucovorin calcium injection recon soln 100 mg, 350 mg
- levalbuterol HCl inhalation solution for nebulization 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/0.5 mL
- levetiracetam in NaCl (iso-os)
- levetiracetam intravenous
- levocarnitine (with sugar)
- levocarnitine intravenous
- levocarnitine oral tablet
- levofloxacin intravenous
- levoleucovorin calcium
- lidocaine (PF) injection solution 5 mg/mL (0.5 %)
- lidocaine HCl injection solution 20 mg/mL (2 %)
- magnesium sulfate injection
- melphalan HCl
- meropenem intravenous recon soln 500 mg
- mesna
- methadone injection
- methotrexate sodium (PF)
- methotrexate sodium oral
- methylprednisolone acetate
- methylprednisolone sodium succ injection recon soln 125 mg, 40 mg
- metoclopramide HCl injection solution
- metoprolol tartrate intravenous
- Miacalcin injection
- mitomycin intravenous recon soln 20 mg
- mitoxantrone

Updated: 09/2016

H0811_GN134_Web Prior Auth_Approved

- morphine intravenous syringe 10 mg/mL, 8 mg/mL
- Mozobil
- Mustargen
- mycophenolate mofetil
- mycophenolate sodium
- nafcillin in dextrose iso-osm intravenous piggyback 1 gram/50 mL
- nafcillin injection recon soln 1 gram
- nafcillin injection recon soln 10 gram
- Naglazyme
- nalbuphine injection solution 10 mg/mL, 20 mg/mL
- Nebupent
- Neoral
- Nephramine 5.4 %
- nitroglycerin intravenous
- Normosol-M in 5 % dextrose
- Normosol-R in 5 % dextrose
- Normosol-R pH 7.4
- Nulojix
- ondansetron
- ondansetron HCl (PF)
- ondansetron HCl oral
- Orenicia (with maltose)
- oxacillin in dextrose(iso-osm) intravenous piggyback 1 gram/50 mL
- oxacillin in dextrose(iso-osm) intravenous piggyback 2 gram/50 mL
- oxacillin injection recon soln 10 gram
- oxacillin intravenous recon soln 2 gram
- oxaliplatin intravenous solution 100 mg/20 mL
- paclitaxel
- pamidronate intravenous solution
- paricalcitol oral
- penicillin G potassium injection recon soln 5 million unit
- penicillin G procaine intramuscular syringe 1.2 million unit/2 mL
- penicillin G sodium
- Pentam
- Perforomist
- Perjeta
- phenytoin sodium intravenous solution
- piperacillin-tazobactam intravenous recon soln 3.375 gram, 4.5 gram
- Plasma-Lyte 148
- Plasma-Lyte A
- Plasma-Lyte-56 in 5 % dextrose
- potassium chlorid-D5-0.45%NaCl
- potassium chloride in 0.9%NaCl intravenous parenteral solution 20 mEq/L, 40 mEq/L
- potassium chloride in 5 % dex intravenous parenteral solution 20 mEq/L, 40 mEq/L
- potassium chloride in LR-D5 intravenous parenteral solution 20 mEq/L
- potassium chloride-D5-0.2%NaCl intravenous parenteral solution 20 mEq/L
- potassium chloride-D5-0.3%NaCl intravenous parenteral solution 20 mEq/L
- potassium chloride-D5-0.9%NaCl
- Premarin injection
- Premasol 10 %
- Premasol 6 %
- Procalamine 3%
- Proleukin
- Prolia
- propranolol intravenous
- Prosol 20 %
- Pulmozyme
- ranitidine HCl injection solution 25 mg/mL
- Rapamune
- Recombivax HB (PF) intramuscular suspension 10 mcg/mL, 40 mcg/mL
- Recombivax HB (PF) intramuscular syringe
- Remodulin
- Rheumatrex
- rifampin intravenous
- ringers intravenous
- Risperdal Consta
- Sancuso
- Sandimmune oral
- Simulect intravenous recon soln 20 mg
- sirolimus
- Solu-Cortef (PF) injection recon soln 100 mg/2 mL, 250 mg/2 mL
- Somatuline Depot
- Somavert

Updated: 09/2016

H0811_GN134_Web Prior Auth_Approved

- streptomycin intramuscular
- sulfamethoxazole-trimethoprim intravenous
- Synercid
- Synribo
- tacrolimus oral capsule 0.5 mg, 1 mg
- tacrolimus oral capsule 5 mg
- Teflaro
- terbutaline subcutaneous
- testosterone cypionate
- testosterone enanthate
- tetanus-diphtheria toxoids-Td
- tobramycin in 0.225 % NaCl
- tobramycin sulfate injection solution
- Toposar
- topotecan intravenous recon soln
- tranexamic acid intravenous
- Travasol 10 %
- Treanda intravenous recon soln 100 mg
- Trelstar intramuscular suspension for reconstitution
- Trelstar intramuscular syringe 11.25 mg/2 mL, 3.75 mg/2 mL
- Trisenox
- TrophAmine 10 %
- Trophamine 6%
- Twinrix (PF) intramuscular suspension
- valproate sodium
- vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg
- Velcade
- verapamil intravenous solution
- vinblastine intravenous solution
- Vincasar PFS intravenous solution 1 mg/mL
- vincristine intravenous solution 1 mg/mL
- vinorelbine intravenous solution 50 mg/5 mL
- Virazole
- voriconazole intravenous
- VPRIV
- Xgeva
- Zaltrap intravenous solution 100 mg/4 mL (25 mg/mL)
- Zemplar intravenous
- zoledronic acid intravenous solution
- zoledronic acid-mannitol-water intravenous solution
- Zometa intravenous solution 4 mg/100 mL
- Zortress
- Zyprexa Relprevv intramuscular suspension for reconstitution 210 mg

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

Index

A

Abelcet	147
Abilify Maintena.....	147
Abraxane	147
acetylcysteine.....	147
Actemra.....	147
Acthar H.P.....	1
Actimmune.....	2
acyclovir sodium.....	147
Adagen	147
adapalene topical cream.....	130
adapalene topical gel.....	130
Adcirca.....	3
Adempas	4
Adrucil	147
Afinitor.....	5
Afinitor Disperz	5
A-Hydrocort.....	147
albuterol sulfate.....	147
Aldurazyme.....	147
Alecensa.....	6
Alimta	147
alprazolam.....	46
AmBisome	147
amifostine crystalline.....	147
amikacin.....	147
amino acids 15 %	147
Aminosyn 8.5 %-electrolytes.....	147
Aminosyn II 10 %	147
Aminosyn II 15 %	147
Aminosyn II 7 %	147
Aminosyn II 8.5 %	147
Aminosyn II 8.5 %-electrolytes	147
Aminosyn M 3.5 %	147
Aminosyn-HBC 7%	147
Aminosyn-PF 10 %	147
Aminosyn-PF 7 % (sulfite-free).....	147
Aminosyn-RF 5.2 %	147
amiodarone.....	147
amitriptyline.....	48
amphotericin B.....	147
ampicillin sodium.....	147
ampicillin-sulbactam.....	147
Ampyra	7

APOKYN.....	9
Aptiom	10
Aralast NP.....	147
Arcalyst	11
Astagraf XL	147
Avastin	147
Avelox in NaCl (iso-osmotic).....	147
Avonex (with albumin).....	12
Avonex intramuscular pen injector kit.....	12
Avonex intramuscular syringe kit.....	12
Azasan.....	147
azathioprine.....	147
azathioprine sodium.....	147
azithromycin	147

B

BACiiM.....	147
bacitracin.....	147
Banzel oral tablet	13
BCG vaccine, live (PF)	147
Beleodaq	147
Benlysta.....	147
benztropine.....	147
benztropine oral	45
bexarotene	123
Bicillin C-R.....	147
BiCNU	147
bleomycin.....	147
Bosulif.....	14
Briviact.....	15
budesonide	147
buprenorphine HCl.....	147
Busulfex	147
butalbital-acetaminop-caf-cod	45

C

Cabometyx	16
calcitriol	147
Cancidas.....	147
Capastat.....	147
Carbaglu.....	17
carboplatin.....	147
cefazolin.....	147
cefazolin in dextrose (iso-os).....	147
cefepime.....	147
cefotaxime.....	147

Updated: 09/2016

H0811_GN134_Web Prior Auth_Approved

cefoxitin	147
cefoxitin in dextrose, iso-osm	147
ceftazidime	147
ceftriaxone.....	147
cefuroxime sodium.....	147
CellCept	148
CellCept Intravenous	147
Cerezyme	148
chloramphenicol sod succinate	148
Cholbam.....	18
chorionic gonadotropin, human	19
Cialis oral tablet 2.5 mg, 5 mg.....	20
cidofovir.....	148
Cimzia Powder for Reconst	148
Cinryze.....	21
ciprofloxacin lactate.....	148
cisplatin	148
cladribine.....	148
clemastine oral tablet 2.68 mg	45
clindamycin phosphate.....	148
Clinimix 5%/D15W Sulfite Free	148
Clinimix 5%/D25W sulfite-free.....	148
Clinimix 2.75%/D5W Sulfite Free	148
Clinimix 4.25%/D10W Sulf Free	148
Clinimix 4.25%/D5W Sulfite Free	148
Clinimix 4.25%-D20W sulf-free	148
Clinimix 4.25%-D25W sulf-free	148
Clinimix 5%-D20W(sulfite-free).....	148
Clinimix E 2.75%/D10W Sul Free	148
Clinimix E 2.75%/D5W Sulf Free	148
Clinimix E 4.25%/D10W Sul Free	148
Clinimix E 4.25%/D25W Sul Free	148
Clinimix E 4.25%/D5W Sulf Free	148
Clinimix E 5%/D15W Sulfite Free.....	148
Clinimix E 5%/D20W Sulfite Free.....	148
Clinimix E 5%/D25W Sulfite Free.....	148
clomipramine	48
clonazepam	47
clorazepate dipotassium	47
colistin (colistimethate Na)	148
Cometriq	22
Copaxone subcutaneous syringe 20 mg/mL, 40 mg/mL.....	23
Cotellic.....	24
cromolyn	148
Cubicin.....	148

cyclobenzaprine oral tablet	45
cyclophosphamide.....	148
cyclosporine	148
cyclosporine modified.....	148
cyproheptadine.....	45
Cyramza	25
cytarabine.....	148

D

D2.5 %-0.45 % sodium chloride.....	148
D5 % and 0.9 % sodium chloride	148
D5 %-0.45 % sodium chloride.....	148
dacarbazine	148
Darzalex	26
daunorubicin	148
decitabine	148
Delestrogen	148
Demser	27
Depen Titratabs.....	89
Depo-Provera	148
dexamethasone sodium phosphate.....	148
dexrazoxane HCl.....	148
dextrose 10 % and 0.2 % NaCl	148
dextrose 10 % in water (D10W)	148
dextrose 5 % in water (D5W)	148
dextrose 5 %-lactated ringers.....	148
dextrose 5%-0.2 % sod chloride	148
dextrose 5%-0.3 % sod.chloride	148
Dextrose With Sodium Chloride.....	148
Dextrose-KCl-NaCl	148
Diastat	47
Diazepam Intensol	47
diazepam oral solution 5 mg/5 mL (1 mg/mL)	47
diazepam oral tablet	47
diazepam rectal	47
diclofenac sodium topical gel 3 %	28
dicyclomine oral capsule.....	45
dicyclomine oral solution.....	45
dicyclomine oral tablet.....	45
Digitek.....	45
digoxin injection solution	45
digoxin oral solution 50 mcg/mL.....	45
digoxin oral tablet	45
diltiazem HCl.....	148
diphenhydramine HCl.....	148
doxepin oral	48

Updated: 09/2016

H0811_GN134_Web Prior Auth_Approved

doxorubicin	148
doxorubicin, peg-liposomal	148
Doxy-100	148
doxycycline hyclate	148
dronabinol	148
Duramorph (PF)	148
E	
Egrifta subcutaneous recon soln 1 mg	29
Elaprase	148
Elelyso	148
Eligard	67
Elitek	148
Emend	148
Empliciti	30
Engerix-B (PF)	148
Engerix-B Pediatric (PF)	148
Envarsus XR	148
epirubicin	148
ergoloid	45
Erivedge	31
Erwinaze	32
Erythrocin	148
Esbriet	33
esomeprazole sodium	148
estradiol oral	48
estradiol valerate	148
etoposide	148
Extavia subcutaneous kit	34
F	
Fabrazyme	148
famotidine (PF)	148
famotidine (PF)-NaCl (iso-os)	148
Farydak	35
Faslodex	148
fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg	129
Ferriprox oral tablet	36
Firazyr	37
fluconazole in dextrose(iso-o)	148
fluconazole in NaCl (iso-osm)	149
fludarabine	149
fluorouracil	149
fluphenazine decanoate	149
fluphenazine HCl	149
fomepizole	149

fosphenytoin	149
furosemide	149
Fycompa oral suspension	38
Fycompa oral tablet	38
G	
Gammagard Liquid	56
Gamunex-C injection solution 1 gram/10 mL (10 %)	56
ganciclovir sodium	149
Gattex One-Vial	39
gemcitabine	149
Gengraf	149
gentamicin	149
gentamicin in NaCl (iso-osm)	149
Geodon	149
Gilotrif	40
Glatopa	23
Gleevec oral tablet 100 mg, 400 mg	41
granisetron (PF)	149
granisetron HCl	149
H	
haloperidol decanoate	149
haloperidol lactate	149
Harvoni	43
heparin (porcine)	149
heparin (porcine) in 5 % dex	149
Hepatamine 8%	149
Herceptin	149
Hetlioz	44
hydralazine	149
hydromorphone (PF)	149
hydroxyprogesterone caproate	49
hydroxyzine HCl	149
I	
Ibrance	50
Iclusig	51
idarubicin	149
ifosfamide	149
Ilaris (PF)	52
Imbruvica	53
imipenem-cilastatin	149
imipramine HCl	48
imipramine pamoate	48
Increlex	149
Inlyta	54
Intralipid	149

Intron A.....	149
Invanz.....	149
Invega Sustenna	149
Invega Trinza	149
Ionosol-B in D5W.....	149
Ionosol-MB in D5W	149
ipratropium bromide	149
ipratropium-albuterol	149
Iressa	55
irinotecan.....	149
Istodax	149

J

Jakafi oral tablet 10 mg, 15 mg, 20 mg, 25 mg, 5 mg	57
Juxtapid	58

K

Kadcyla	149
Kalydeco	59
Keveyis	60
Keytruda.....	149
Korlym	62
Kuvan oral tablet,soluble	63

L

labetalol.....	149
Lanoxin oral	45
Lenvima	64
Letairis	65
leucovorin calcium.....	149
Leukine injection recon soln.....	66
levalbuterol HCl.....	149
levetiracetam	149
levetiracetam in NaCl (iso-os)	149
levocarnitine.....	149
levocarnitine (with sugar)	149
levofloxacin.....	149
levoleucovorin calcium	149
lidocaine (PF).....	149
lidocaine HCl	149
lidocaine topical adhesive patch,medicated	68
linezolid intravenous	146
linezolid oral suspension for reconstitution	146
linezolid oral tablet	146
Lonsurf.....	69
Lorazepam Intensol.....	46

lorazepam oral tablet.....	46
Lupron Depot	67
Lupron Depot (3 Month).....	67
Lupron Depot (4 Month).....	67
Lupron Depot (6 Month).....	67
Lupron Depot-Ped intramuscular kit 11.25 mg, 15 mg	67
Lynparza	70

M

magnesium sulfate	149
megestrol oral tablet.....	48
Mekinist	71
melphalan HCl	149
memantine.....	72
meprobamate.....	45
meropenem.....	149
mesna	149
metaxalone	45
methadone	149
methotrexate sodium	149
methotrexate sodium (PF).....	149
methyl dopa-hydrochlorothiazide	45
methylprednisolone acetate.....	149
methylprednisolone sodium succ	149
metoclopramide HCl.....	149
metoprolol tartrate.....	149
Miacalcin.....	149
mitomycin	149
mitoxantrone	149
modafinil	80
morphine	150
Mozobil	150
Mustargen	150
mycophenolate mofetil.....	150
mycophenolate sodium	150

N

nafcillin	150
nafcillin in dextrose iso-osm.....	150
Naglazyme	150
nalbuphine.....	150
Namenda	72
Namenda Titration Pak	72
Namenda XR.....	72
Natpara.....	73
Nebupent.....	150
Neoral.....	150

Updated: 09/2016

H0811_GN134_Web Prior Auth_Approved

Nephramine 5.4 %	150
Neupogen	74
Neupro.....	75
Nexavar	76
Ninlaro	77
nitroglycerin.....	150
Norditropin FlexPro.....	42
Normosol-M in 5 % dextrose.....	150
Normosol-R in 5 % dextrose.....	150
Normosol-R pH 7.4.....	150
Northera	78
Novarel.....	19
Nulojix	150
Nuplazid.....	79

O

octreotide acetate injection solution 1,000 mcg/mL, 500 mcg/mL	81
octreotide acetate injection solution 100 mcg/mL, 200 mcg/mL, 50 mcg/mL.....	81
Odomzo.....	82
Ofev.....	83
Oncaspar	84
ondansetron	150
ondansetron HCl	150
ondansetron HCl (PF)	150
Onfi oral suspension	85
Onfi oral tablet 10 mg, 20 mg.....	85
Opdivo intravenous solution 40 mg/4 mL	86
Opsumit.....	87
Orencia (with maltose).....	150
oxacillin.....	150
oxacillin in dextrose(iso-osm).....	150
oxaliplatin	150
oxazepam	46

P

paclitaxel	150
pamidronate.....	150
paricalcitol.....	150
PegIntron.....	88
PegIntron Redipen	88
penicillin G potassium	150
penicillin G procaine.....	150
penicillin G sodium.....	150
Pentam.....	150
Perforomist.....	150
Perjeta	150

perphenazine-amitriptyline	48
phenobarbital.....	48
phenoxybenzamine	90
phenytoin sodium.....	150
piperacillin-tazobactam.....	150
Plasma-Lyte 148	150
Plasma-Lyte A	150
Plasma-Lyte-56 in 5 % dextrose.....	150
Pomalyst.....	91
potassium chlorid-D5-0.45%NaCl.....	150
potassium chloride in 0.9%NaCl	150
potassium chloride in 5 % dex	150
potassium chloride in LR-D5.....	150
potassium chloride-D5-0.2%NaCl.....	150
potassium chloride-D5-0.3%NaCl.....	150
potassium chloride-D5-0.9%NaCl.....	150
Potiga	92
Praluent Pen subcutaneous pen injector	150
mg/mL, 75 mg/mL.....	93
Praluent Syringe subcutaneous syringe	150
mg/mL, 75 mg/mL	93
Pregnyl	19
Premarin.....	150
Premasol 10 %	150
Premasol 6 %	150
Procalamine 3%	150
Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL	95
Proleukin	150
Prolia	150
Promacta oral tablet 12.5 mg, 25 mg, 50 mg	97
promethazine oral tablet.....	45
propranolol.....	150
Prosol 20 %	150
Pulmozyme	150

Q

quinine sulfate	98
-----------------------	----

R

ranitidine HCl.....	150
Rapamune	150
Ravicti	99
Rebif (with albumin).....	100

Updated: 09/2016

H0811_GN134_Web Prior Auth_Approved

Rebif Rebidose subcutaneous pen injector	
22 mcg/0.5 mL, 44 mcg/0.5 mL,	
8.8mcg/0.2mL-22 mcg/0.5mL (6)	100
Rebif Titration Pack	100
Recombivax HB (PF).....	150
Remicade.....	101
Remodulin.....	150
Repatha SureClick	103
Repatha Syringe	103
reserpine.....	45
Revlimid.....	106
Rheumatrex	150
ribavirin oral capsule.....	107
ribavirin oral tablet 200 mg.....	107
rifampin.....	150
ringers	150
Risperdal Consta	150
Rituxan.....	108
S	
Sabril	109
Samsca oral tablet 15 mg, 30 mg	110
Sancuso	150
Sandimmune	150
Sandostatin LAR Depot intramuscular	
suspension,extended rel recon	111
Signifor	112
sildenafil oral	105
Simulect	150
sirolimus.....	150
Solu-Cortef (PF).....	150
Somatuline Depot.....	150
Somavert	150
Sovaldi	113
Sprycel oral tablet 100 mg, 140 mg, 20 mg,	
50 mg, 70 mg, 80 mg	114
Stivarga	115
streptomycin.....	151
sulfamethoxazole-trimethoprim	151
Surmontil.....	48
Sutent	116
Sylatron	117
Synagis intramuscular solution 50 mg/0.5	
mL	118
Synercid	151
Synribo.....	151

T	
tacrolimus.....	151
Tafinlar.....	120
Tagrisso.....	121
Tarceva oral tablet 100 mg, 150 mg, 25 mg	
.....	122
Targretin oral	123
Tasigna.....	124
Tecentriq	125
Teflaro	151
temazepam	46
terbutaline	151
testosterone cypionate	151
testosterone enanthate	151
tetanus-diphtheria toxoids-Td	151
tetrabenazine	139
Thalomid	126
thioridazine	127
thiotepa.....	128
tobramycin in 0.225 % NaCl	151
tobramycin sulfate.....	151
topiramate oral capsule, sprinkle	8
topiramate oral capsule,sprinkle,ER 24hr ...	8
topiramate oral tablet	8
Toposar	151
topotecan	151
tranexamic acid	151
Travasol 10 %	151
Treanda	151
Trelstar	151
tretinoin microspheres topical gel with pump	
.....	130
tretinoin topical	130
trihexyphenidyl	45
trimipramine.....	48
Trisenox	151
TrophAmine 10 %.....	151
Trophamine 6%.....	151
Twinrix (PF).....	151
Tykerb	131
Tysabri	132
V	
valproate sodium	151
vancomycin	151
Velcade	151
Venclexta	134

Venclexta Starting Pack	134	Xtandi.....	141
verapamil.....	151	Y	
Viekira Pak.....	135	Yervoy intravenous solution 50 mg/10 mL	
Vimpat intravenous.....	136	(5 mg/mL)	142
Vimpat oral solution	136	Z	
Vimpat oral tablet	136	Zaltrap	151
vinblastine	151	Zelboraf.....	143
Vincasar PFS.....	151	Zemplar	151
vincristine.....	151	zoledronic acid.....	151
vinorelbine	151	zoledronic acid-mannitol-water	151
Virazole.....	151	Zometa	151
voriconazole.....	151	zonisamide	8
Votrient	137	Zortress	151
VPRIV.....	151	Zydelig	144
X		Zykadia	145
Xalkori	138	Zyprexa Relprevv.....	151
Xenazine	139	Zyvox intravenous parenteral solution 600	
Xgeva	151	mg/300 mL.....	146
Xolair	140	Zyvox oral.....	146

GuildNet Gold Plus FIDA Plan is a managed care plan that contracts with both Medicare and New York State Department of Health (Medicaid) to provide benefits of both programs to Participants through the Fully Integrated Duals Advantage (FIDA) Demonstration.

Beneficiaries must use network pharmacies to access their premium and/or copayment/coinsurance may change on January 1, 2017.

This document includes GuildNet Gold Plus FIDA Plan's partial formulary as of September 1, 2016. For a complete, updated formulary, please visit our website at www.guildnetny.org or call 1-800-815-0000 (TTY 1-800-662-1220).

For alternative formats or language, please call Participant Services toll free at: 1-800-815-0000, Monday through Sunday from 8am to 8pm. TTY/TDD users should call 1-800-662-1220.

You can get this information for free in other languages. Call 1-800-815-0000 and TTY/TDD 1-800-662-1220 during 8am to 8pm. The call is free.

Usted puede obtener esta información en otros idiomas gratis. Llame al 1-800-815-0000 o TTY/TDD al 1-800-662-1220, de lunes a domingo de 8am a 8pm. La llamada es gratis.

Queste informazioni sono disponibili gratuitamente in altre lingue. Chiamare il numero verde 1-800-815-0000 o 1-800-662-1220 mediante un telefono testuale per non udenti (TTY/TDD), da lunedì a domenica, dalle 8 alle 20. La chiamata è gratuita.

您可以免費獲得本信息的其他語言版本。請撥打 1-800-815-0000 或聽障／語障人士專線 (TTY/TDD) 1-800-662-1220，星期一至星期日上午 8 時至晚上 8 時。撥打該電話免費。

Ou kapab jwenn enfòmasyon sa yo gratis nan lòt lang. Rele nimewo 1-800-815-0000 oswa TTY/TDD 1-800-662-1220, lendi jiska dimanch, depi 8am jiska 8pm. Koutfil la gratis.

다른 언어로 작성된 이 정보를 무료로 얻으실 수 있습니다. 월요일 - 일요일 오전 8시부터 오후 8시 사이에 1-800-815-0000번이나 TTY/TDD 1-800-662-1220번으로 전화주세요. 통화는 무료입니다.

Вы можете бесплатно получить эту информацию на других языках. Позвоните по телефону 1-800-815-0000 и TTY/TDD 1-800-662-1220. Служба работает с понедельника по воскресенье с 08:00 до 20:00 ч. Звонок бесплатный.

The State of New York has created a participant ombudsman program called the Independent Consumer Advocacy Network (ICAN) to provide Participants free, confidential assistance on any services offered by GuildNet Gold Plus FIDA Plan. ICAN may be reached toll-free at 1-844-614-8800 or online at icannys.org.

16143 v14

Updated: 09/2016
H0811_GN134_Web Prior Auth_Approved